Mabwell (Shanghai) Bioscience Co., Ltd.

Mabwell (Shanghai) Bioscience Co., Ltd. is an innovation-driven biopharmaceutical company with integrated capabilities spanning research and development, manufacturing, and commercialization. Headquartered in Shanghai, China, the company is committed to providing effective and accessible innovative medicines and biosimilars to address global medical needs. Its mission is to "explore life to benefit health," with a vision of "Innovation, from Ideas to Reality."

The company's core business focuses on developing a diverse portfolio of therapeutic agents, including antibodies, antibody-drug conjugates (ADCs), recombinant proteins, and small-molecule chemical drugs. Mabwell's robust pipeline includes 15 high-priority candidates, comprising 11 novel drugs and 4 biosimilars, targeting various therapeutic areas such as oncology, immunology, bone disorders, ophthalmology, hematology, cardiovascular disease, infectious diseases, and aging-related conditions. Four of its products, MAIWEIJIAN, MALISHU, MAILISHENG, and JUNMAIKANG, have already been approved and commercialized.

In recent news, Mabwell completed a dual listing on the Main Board of the Hong Kong Stock Exchange (HKEX) on April 28, 2026, under the ticker 02493.HK, complementing its existing listing on the Shanghai Stock Exchange (SSE) STAR Market (688062.SH). The company also announced the publication of a clinical case report for its Nectin-4 ADC (9MW2821) in The New England Journal of Medicine in April 2026 and initiated a Phase III clinical study for 9MW2821 for triple-negative breast cancer. Furthermore, Mabwell has secured significant licensing deals, including a potential US$600 million agreement with Calico Life Sciences for 9MW3811 in June 2025 and a potential US$412.5 million deal with Disc Medicine for 9MW3011 in January 2023. Datao Liu serves as the Chairman, Executive Director, and General Manager.